MindRank AI Wins Championship at China Bioindustry Conference 2025 Biomanufacturing Innovation & Entrepreneurship Competition and Files IPO Prospectus
MindRank
AI Drug Developer
Recently, the China Bio-Industry Conference2025 Biomanufacturing Innovation and Entrepreneurship Competition FinalsSuccessfully concluded. After fierce competition, MindRank was awarded the competition for its breakthrough achievements in AI-driven new drug development.Champion。
As an important part of the China Bio-Industry Conference, this competition was held in the format of "offline roadshow + on-site defense." A jury composed of senior experts in the biomanufacturing field and representatives from investment institutions conducted multi-dimensional professional evaluations of the participating projects. MindRank stood out with its exceptional technological innovation capabilities and clear industrialization pathway, earning unanimous praise from the judges.
MindRank Reshapes Traditional Logic of Drug R&D with Artificial Intelligence Technology, Significantly Enhancing R&D Efficiency and Substantially Reducing Preclinical Costs, Making It Possible for New Drug Development to Break the "10 Years + $1 Billion" Conventional R&D Rule. Currently, the company has built an industrial-grade one-stop AI new drug R&D platform with proprietary intellectual property rights, covering AI drug design, protein dynamic simulation, and knowledge graph data mining systems, empowering the entire process from target discovery to customized drug design. Its first AI-assisted designed GLP-1RA oral small molecule new drug, MDR-001, took only 19 months from project initiation to entering clinical trials, improving efficiency by over 50% compared to traditional R&D models. As of May 2025, MDR-001 has successfully completed Phase IIb clinical trials, showing a 10.3% weight loss in patients over 24 weeks, with excellent safety and tolerability. Phase III clinical trials are expected to commence in the second half of the year.
MindRank's triumph this time not only demonstrates its leading position in the AI pharmaceutical field but also injects strong momentum into the high-quality innovative development of China's biopharmaceutical industry.
About MindRank
MindRank is a clinical-stage AI-driven innovative drug discovery company. The company's vision is to continuously deliver differentiated and high-clinical-value drug candidates by promoting the integration of various cutting-edge technologies in artificial intelligence and new drug development, thereby making more diseases treatable and restoring health to more lives.
The company owns a self-developed, internationally leading industrial-grade one-stop AI-driven innovative drug research and development platform, including the knowledge graph-based data mining platform PharmKG™, the protein dynamic simulation and structure prediction platform Molecule Dance™, and the one-stop AI drug design platform Molecule Pro™.
MindRank's AI pharmaceutical solutions were rated by the authoritative European and American institution Deep Pharma Intelligence as one of the "11 most important AI drug R&D breakthrough achievements globally from 2018 to 2020." In 2023, it was included in Forbes' "Forbes Asia 100 to Watch" list, with only 11 startups from mainland China making the list. In 2024, it was selected for Fortune magazine's IMPACT Enterprise List as one of "China's most socially influential entrepreneurial companies."
MindRank's Self-Developed One-Stop AI Pharmaceutical Platform
Related Reading:
MindRank's Self-Developed WEE1/YES1 Dual Inhibitor Receives FDA Clinical Approval in the U.S.
MindRank Selected as One of the Top 100 Companies to Watch in the 2023 Forbes Asia-Pacific Region
For more information, please visit the website: www.mindrank.ai
Contact: bd@mindrank.ai pr@mindrank.ai
Other: info@mindrank.ai